Physician profile
Samya Bayan Shafi
NPI 1992813398
$4,110.83
in general payments reported to CMS, 2019-2025
22 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.16 · 2020: $48.69 · 2021: $480 · 2022: $978 · 2023: $1,343 · 2024: $794 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,018.29 | 2020-2025 | Dalvance, Teflaro, Mavyret |
| Shionogi INC | $475.80 | 2020-2024 | Fetroja |
| Merck Sharp & Dohme LLC | $435.25 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Insmed, INC. | $399.79 | 2022-2025 | Arikayce |
| Gilead Sciences, INC. | $397.29 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $340.61 | 2021-2025 | Cabenuva, Apretude |
| Paratek Pharmaceuticals, INC. | $219.02 | 2020-2025 | Nuzyra |
| Janssen Biotech, INC. | $172.13 | 2021-2023 | Symtuza, Tremfya, Simponi Aria |
| Astellas Pharma US INC | $167.46 | 2023 | Cresemba |
| La Jolla Pharmaceutical Company | $98.89 | 2021-2023 | Xerava |
| Melinta Therapeutics, LLC | $88.06 | 2022 | |
| Allergan, INC. | $48.16 | 2019 | |
| Abbott Laboratories | $40.45 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $35.31 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.36 | 2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $28.53 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Sandoz INC. | $21.58 | 2023 | Hyrimoz |
| Amryt Pharma Holdings LTD | $19.42 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.31 | 2023 | Strensiq |
| Cumberland Pharmaceuticals, INC. | $14.66 | 2023 | Vibativ |
| Lilly USA, LLC | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samya Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.